Fudan University
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 384
- Registration Number
- NCT05860907
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The Fourth Hospital of Hebei Medical University, Shijia Zhuang, Hebei, China
🇨🇳The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China
Postoperative Effects of Different Enterostomy Approaches
- Conditions
- Intestinal Neoplasms, MalignantColorectal CancerColorectal Neoplasms Malignant
- Interventions
- Procedure: IleostomyProcedure: Transverse colostomy
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 300
- Registration Number
- NCT05853094
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Multi-dimensional Fragmentomic Assay for Early Detection of Pancreatic Neuroendocrine Tumors
- Conditions
- Pancreatic Neuroendocrine Tumor
- Interventions
- Diagnostic Test: Blood collection
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 440
- Registration Number
- NCT05847855
- Locations
- 🇨🇳
Fudan University shanghai cancer center, Shanghai, Shanghai, China
Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRT
- Conditions
- Neoplasm, Squamous CellNeoplasm, Esophagus
- Interventions
- Procedure: nCRT
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 187
- Registration Number
- NCT05839002
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 876
- Registration Number
- NCT05841381
Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer
- Conditions
- Pancreatic Neoplasms
- Interventions
- Drug: QingyiHuaji optimized formula
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 306
- Registration Number
- NCT05840341
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients
- Conditions
- Breast Cancer
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 161
- Registration Number
- NCT05839288
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma
- Conditions
- High-Risk Localized Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT05839275
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)
- Conditions
- Advanced Intrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05835245
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05823987
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China